JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target

Benzinga · 2d ago
JP Morgan analyst Jessica Fye reinstates MBX Biosciences (NASDAQ:MBX) with a Overweight and announces $88 price target.